LivaNova Beats Q1 with $0.98 EPS, Raises 2026 Revenue Growth to 8%
LIVN•LivaNova posted Q1 adjusted EPS of $0.98 beating estimates by $0.08 and revenue of $362.3 million, up 14.3% year-over-year. The company raised its full-year 2026 revenue growth guidance to 7.0%-8.0% CC and EPS outlook to $4.20-$4.30, though shares fell over 2% premarket.
1. Q1 Results Beat Estimates
LivaNova reported adjusted earnings per share of $0.98, exceeding consensus by $0.08, while revenue climbed 14.3% year over year to $362.3 million on an 11.1% constant-currency gain. Shares fell more than 2% in premarket trading as investors weighed the outlook.
2. Raised Full-Year 2026 Guidance
The company lifted its full-year revenue growth guidance to 7.0%-8.0% on a constant-currency basis from 6.0%-7.0% and increased adjusted diluted EPS guidance to $4.20-$4.30, with a mid-point of $4.25 slightly above analyst consensus of $4.21.
3. Segment Performance Drivers
Cardiopulmonary sales surged 18.3% to $208.7 million, driven by strong Essenz Perfusion System orders and consumables demand, while Neuromodulation revenue rose 9.3% to $151.8 million on higher implant procedure volumes and favorable pricing trends.
4. FDA Approval and Cash Flow Guidance
During the quarter, LivaNova secured FDA premarket approval for its aura6000 hypoglossal nerve stimulation system without complete concentric collapse contraindications, marking a key sleep apnea milestone. The company maintained full-year free cash flow guidance at $160 million to $180 million.
